Unifrax and Clearlake Announce Battery Advisory Board to Support Breakthrough Silicon Fiber Anode Battery Technology, Thermal Run-Away and Separator Products
Unifrax, a leading manufacturer of high-performance specialty materials, today introduced its Battery Advisory Board, which will meet regularly to provide strategic guidance as Unifrax grows its battery portfolio and enters the silicon anode market with its new SiFAB™ Silicon Fiber Anode Battery Technology.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20211111005282/en/
SiFAB, a scalable proprietary silicon anode battery technology demonstrated in wide-reaching applications, including electric vehicles, power tools, smartphones, personal computers, medical devices and aviation, can deliver up to 20% increase in gravimetric energy density in lithium-ion batteries. It has proven through advanced testing high reversible capacity of greater than 1,000 mAh/g. Unifrax recently broke ground on its first production line located in New Carlisle, IN, which is expected to come online in early 2022.
This transformational technology becomes part of a robust battery portfolio that also consists of world class thermal management products and separator media.
The advisory board will bring together four highly experienced professionals and visionaries in the battery technology, engineering and operations space, with experts from the nation’s top universities and esteemed technology companies.
Unifrax’s Battery Advisory Board will include:
- Dr. Prabhakar Patil, former CEO, LG Chem Power, and Chief Engineer of Hybrid Technologies, Ford Motor Company. Dr. Patil previously served as CEO of LG Chem Power (LGCPI) for 10 years. Prior to joining LGCPI in 2005, Dr. Patil spent 27 years of his professional career at Ford Motor Company in various engineering and management positions. He served as Chief Engineer for Ford’s hybrid technologies during 2003 and was also Chief Engineer for the Ford Escape Hybrid from 1998 to 2003.
- Rita Lane, former Vice President of Operations, Apple Inc., and Senior Vice President of Integrated Supply Chain, Motorola. Ms. Lane has more than 30 years of experience building and leading global hardware operations and supply chain teams for Fortune 100 companies. From 2008 until her retirement in 2014, she served as Vice President of Operations at Apple, where she oversaw the launch of the iPad and manufacturing of the Mac desktop and accessories product lines. From 2006 to 2008, Lane was Chief Procurement Officer and SVP, Supply Chain, at Motorola. Prior to working at Motorola, Lane held various senior-level operations roles at IBM for more than 10 years.
- Dr. Arumugam “Ram” Manthiram, Professor, University of Texas at Austin. Dr. Manthiram is Director of the Texas Materials Institute and the Materials Science and Engineering Graduate Program. With more than 35 years of experience, Dr. Manthiram’s research is focused on the development of low-cost, high-performance materials for batteries. He is a globally recognized leader in cathode materials for lithium-ion batteries. He has authored more than 850 journal articles. Dr. Manthiram holds the Cockrell Family Regents Chair in Engineering #5. He delivered the lecture on behalf of Nobel Prize recipient John B. Goodenough in 2019 in Stockholm for his work on lithium-ion batteries.
- Dr. Jennifer Rupp, Professor of Electrochemical Materials, Massachusetts Institute of Technology (MIT) and TU Munich (TUM). Dr. Rupp is Associate Professor of Electrochemical Materials in the Departments of Materials Science and Engineering at MIT and in the Department of Chemistry at TUM, and technical director of TUM Int. Energy. Dr. Rupp gave keynote lectures at Nature Energy and Sustainability conferences, Gordon Research keynote lectures in ceramics and electrochemistry and at the Royal Chemical Society, and presented on battery, information and energy technology at the World Economic Forum. Dr. Rupp’s team's current research focuses are on solid-state material design and tuning of structure-property relations for novel energy and information devices and operation schemes. In 2021, Rupp was invited to become a Fellow of the Royal Society of Chemistry (FRSC).
“We’re thrilled to have put together such a talented and influential advisory board,” said John Dandolph, CEO, Unifrax. “Their depth of experience and perspective in lithium-ion battery technology and novel chemistries spans multiple industries, including portable electronics, consumer devices and EVs, which will help us navigate the complex supply chains as we bring hundreds of metric tons of capacity to the market in the near future. I look forward to partnering with this group of industry icons as we transform battery safety, capacity, power, and charge times.”
To learn more about SiFAB or to follow the latest updates on the technology, visit www.sifab.com.
About Unifrax
Unifrax develops and manufactures high-performance specialty materials used in advanced applications, including high-temperature industrial insulation, electric vehicles, energy storage, filtration and fire protection, among many others. Unifrax products are designed with the ultimate goal of saving energy, reducing pollution and improving safety for people, buildings and equipment by delivering on our commitment to our customers of greener, cleaner, safer solutions for their application challenges. Unifrax has over 60 global manufacturing facilities and employs 5,600+ employees globally. More information is available at www.unifrax.com. For updates, follow us on Twitter, LinkedIn and Facebook.
About Clearlake
Clearlake Capital Group, L.P. is a leading investment firm founded in 2006 operating integrated businesses across private equity, credit, and other related strategies. With a sector-focused approach, the firm seeks to partner with world-class management teams by providing patient, long-term capital to dynamic businesses that can benefit from Clearlake’s operational improvement approach, O.P.S. ® The firm’s core target sectors are technology, industrials, and consumer. Clearlake currently has approximately $50 billion of assets under management and its senior investment principals have led or co-led over 300 investments. The firm has offices in Santa Monica and Dallas. More information is available at www.clearlake.com and on Twitter @ClearlakeCap.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20211111005282/en/
Contact information
Media:
For Unifrax:
Deborah L. Myers
Director, Global Marketing Communication
dmyers@unifrax.com
716.812.4802
For Clearlake:
Jennifer Hurson
Lambert & Co.
jhurson@lambert.com
845.507.0571
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Ant Group Unveils China’s First Multimodal AI Assistant with Code-Driven Outputs18.11.2025 10:05:00 EET | Press release
Ant Group today launched LingGuang, a next-generation multimodal AI assistant and the first of its kind in China that interacts with users through code-driven outputs. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251117438567/en/ Equipped with the capability to understand and produce language, image, voice and data, LingGuang delivers precise, structured responses to complex queries through 3D models, audio clips, charts, animations, interactive maps, and even immediately generated applications, in addition to traditional text-based conversation. Designed around three key features, LingGuang aims to make complex knowledge simpler and more intuitive, transforming how users access information and interact with AI tools. Fast Research: LingGuang responds to user questions or keywords with dynamic, multimodal content, making research on any topic clearer and more engaging. Its 3D digital modeling capability transcends traditio
SkySparc Appoints Oliver Bussmann as Chairman of the Board18.11.2025 10:00:00 EET | Press release
SkySparc, a trusted global provider of digital transformation solutions for treasury and finance organizations, today announced the appointment of Oliver Bussmann as Chairman of the Board, following the closing of a majority growth investment from Bregal Milestone, a leading European software private equity firm. As former Global CIO at UBS and SAP, Bussmann has a proven track record of scaling B2B software and services across the Office of the CFO, Financial Services, RegTech, and WealthTech. Throughout his career, he has guided organizations through complex SaaS transitions, strategic M&A, and go-to-market acceleration – delivering multiple successful exits and sustained enterprise growth. Bussmann will help steer SkySparc’s technology and value-creation agenda, as Chairman, leveraging his network across financial services and technology to accelerate innovation, expand AI adoption, and drive long-term growth. “We are thrilled to welcome Oliver to SkySparc’s leadership team,” said Jo
European Commission Grants Approval of Remsima™ IV Liquid Formulation, World’s First Liquid Formulation of IV Infliximab18.11.2025 09:23:00 EET | Press release
Celltrion, Inc. today announced that the European Commission (EC) has granted marketing authorization for Remsima™ IV (intravenous) liquid formulation, the world’s first liquid formulation of IV infliximab. Approved in 100 mg and 350 mg vials, the formulation is designed to streamline infusion preparation, reduce healthcare professionals’ workload, and support hospital operational efficiency.3 The Remsima™ IV liquid formulation is approved in the EU for all indications of IV infliximab, matching the approved uses of all existing IV infliximab powder formulations, including rheumatoid arthritis (RA), adult and pediatric Crohn’s disease (CD), ulcerative colitis (UC), pediatric UC, ankylosing spondylitis (AS), psoriatic arthritis (PsA), and psoriasis (PsO).1 The comparability between lyophilized powder formulation and the liquid formulation of IV infliximab has been established through comprehensive chemistry, manufacturing, and controls data.2 The stability of the liquid formulation of I
Swiss-Based Debiopharm Seeks to Boost Innovation in Japanese Cancer Research Through the New "Ideal Japan” Program18.11.2025 09:00:00 EET | Press release
Debiopharm (www.debiopharm.com), a Swiss biopharmaceutical company aiming to cure cancer and infectious diseases, is pleased to announce today the launch of the new IDEAL Japan initiative. This program was initiated to provide financial support to Japanese academic researchers in order to facilitate the transformation of academic innovation into novel therapeutic approaches for combating cancer. IDEAL Japan follows the conclusion of the highly respected JCA (Japanese Cancer Association) Mauvernay Award in Japan, which honored Japanese scientists over the last 20 years, from 2004 through 2024. Debiopharm is now transitioning its historic award into the IDEAL Japan initiative aiming to accelerate preclinical scientific research that could give rise to new treatments for cancer patients. “Our vision is to collaborate to find a cure for cancer,”explained Thierry Mauvernay, President of Debiopharm. “We believe that our ongoing Swiss-Japanese connection needs to evolve and catalyze the trans
Avanzanite Bioscience Secures €32M Series A Investment from MVM Partners18.11.2025 08:00:00 EET | Press release
Avanzanite Bioscience B.V. (Avanzanite), a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today announced a €32 million Series A growth investment from MVM Partners (MVM), a leading global life-science private equity firm. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251117345890/en/ Adam Plich, Founder and CEO of Avanzanite. The announcement follows a record-breaking Q3 2025 for Avanzanite, with revenue tripling year-on-year and climbing over 20% quarter-on-quarter. This strategic funding will accelerate the expansion of Avanzanite’s pan-European infrastructure and propel both current and future rare disease product launches. The capital will also enable Avanzanite to form new strategic alliances and acquire assets to expand its portfolio. Avanzanite was built to solve Europe’s rare-disease medicines access gap. Under one pan-European operation, Avanzanite brings toget
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
